Location: Berlin, Germany
Date: May 21 to May 24
Significant LDL Cholesterol Reductions With ANGPTL3 siRNA in homozygous familial hypercholesterolaemia
Professor Frederick Raal about an interim analysis of a phase 2 study demonstrates that the RNAi therapeutic ARO-ANG3 reduces LDL-c and ApoB in patients with homozygous familial #hypercholesterolaemia.
Do overweight and obesity confer an additional risk of CAD in patients with FH?
Professor Amany Elshorbagy explains, that obese children and adults with heterozygous familial hypercholesterolemia have a higher risk of coronary artery disease compared with HeFH patients with normal weight. A similar trend is observed in patients with homozygous FH. These are the findings of a cross-sectional analysis on 35,919 patients from 46 countries of the EAS FH Studies Collaboration Registry.
Overweight and obesity are common in people with FH and contribute to their already elevated risk of CAD, even from a young age. Holistic management of people with FH should include body weight management where needed, in addition to the lipid-lowering medication, to minimize the risk of CAD events in this population.